Dr. John Cush RheumNow
2 years 9 months ago
AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/gvbPkeq2sH https://t.co/J25U6rWNTy
Dr. John Cush RheumNow
2 years 9 months ago
JAMA: cutaneous hallmarks of dermatomyositis. Printable Patient education overview. https://t.co/S7MaAz6fX2 https://t.co/5ETcQRz8Fd
Dr. John Cush RheumNow
2 years 9 months ago
SGLT2 Inhibitors Reduce Gout Flares and CV Events. A cohort analysis shows that gout patients initiating sodium–glucose cotransporter-2 inhibitors (SGLT2is) had lower serum urate levels and fewer gouty flares requiring ED visits or hospitalizations. https://t.co/laOh4CsZ8Z https://t.co/6oas9AWc8j
Dr. John Cush RheumNow
2 years 9 months ago
Are you up-to-date with the relationship between SpA, its comorbidities, and how it impacts patients? Review this update showcasing a present overview of this topic.
Sponsored by Novartis Medical Affairs. https://t.co/zirCeZ0Fgh https://t.co/HIwVNoV94H
Dr. John Cush RheumNow
2 years 9 months ago
Rheumatoid vasculitis (RV) metanalysis: RV decreased from 9.1 (1988-2000) to 3.9 (2001-2010) per million. RV risk increased w/ smoking, disease duration, seropositivity, males, HLA-DRB104, HLA-C3. Common: skin (65–88%), CNS(35–63%), cardiac (33%) https://t.co/gBxd9EIvo2 https://t.co/NFMSkeAq5d
Dr. John Cush RheumNow
2 years 9 months ago
A double-blind, sham-controlled RCT of auricular vagus nerve stimulation (VNS) showed NO meaningful improvement in 101 RA completers. @week 12, ACR20 was 25% for VNS vs 27% for sham (NS). Also NS was change in DAS28-CRP (–0.95 vs –0.66)(p 0.06) https://t.co/n4e564a3gN https://t.co/mnVliEuafK
Dr. John Cush RheumNow
2 years 9 months ago
Plantar Fasciitis study of 180 PF patients shows no clinically meaningful difference between pts treated with patient advice plus heel cup alone (PA) versus PA and lower limb exercise (PAX) versus PAX plus corticosteroid injection (PAXI) https://t.co/X5Q1MlmkzW https://t.co/NtbLQv6b2q
Dr. John Cush RheumNow
2 years 9 months ago
RheumNow Live 2024 is nearly here!
Among our 25 speakers, Dr. Weber will cover Cardio-Rheumatology Clinic - Identifying CV Risks. Dr. Guma will cover Nutrition in RA. Dr. El Gabalaway will cover the Prevention of RA, all in a session on Success in RA.
https://t.co/5kq9KReEsJ https://t.co/L2GiR8Upqn
Dr. John Cush RheumNow
2 years 9 months ago
AOSD: Young vs. Elderly Onset AOSD is an autoinflammatory condition characterized by fevers, arthritis, & rash. It is considered an orphan disease because of its low prevalence - reported anywhere between 16 to 40 per ten million. https://t.co/vY1yZUX25S
Dr. John Cush RheumNow
2 years 9 months ago
Best of 2023: PMR: glad or bad tidings?
“Life was turned upside down overnight” – PMR patient.
https://t.co/l7jZei5Kfm https://t.co/Ct3qlHd34P
Dr. John Cush RheumNow
2 years 9 months ago
Best of 2023: EULAR/ACR Guidance on Haemophagocytic Lymphohistiocytosis/Macrophage Activation Syndrome
https://t.co/QQ2IEEMQVy https://t.co/M4NHkasFz6
At the 2023 ACR State of the Art conference in Orlando, Florida, Dr. Michelle Petri reviewed the treatment and management of neuropsychiatric lupus. Dr. Petri, a lupus expert from Johns Hopkins Rheumatology, reviewed the latest clinical and animal model studies that offer hope in treatment and gave wide-ranging pearls on a variety of issues that can be faced in this disorder.
Retrospective claims analysis shows that psoriasis patients treated with either an IL-12/23 inhibitor or an IL-23 inhibitor had a lower risk of developing incident psoriatic arthritis, compared to TNF inhibitors or IL-17 inhibitors.
Dr. Jack Cush reviews selected AOSD & systemic JIA abstracts from the ACR 2023 Annual meeting held in San Diego, November 12th thru 16th.
Abstract 0761. EULAR / PreS Recommendations for the Diagnosis and Management of Systemic Juvenile Idiopathic Arthritis (sJIA) and Adult Onset Still’s Disease (AOSD). Fautrel et a.
Dr. John Cush RheumNow
2 years 9 months ago
Best of 2023: Cost-Effective Use of Biological and Targeted Synthetic DMARDs
An international task force of 13 European experts have developed evidence-based points to consider regarding the cost-effective use of biological and targeted synthetic disease.
https://t.co/UAlpww3fmi https://t.co/NpkTgwDuRl
